On April 20, the official wechat of Wuzhong District, Suzhou City, Jiangsu Province announced that Jiangsu Wuzhong Pharmaceutical Development Co.Ltd(600200) ( Jiangsu Wuzhong Pharmaceutical Development Co.Ltd(600200) ), a listed enterprise in the local pharmaceutical sector, took the initiative to contact governments at all levels and the Red Cross Society to understand the demand intention. After collecting and summarizing the needs of relevant parties, it decided to donate 400000 boxes of abidol salt and acid tablets (manosu), with a market value of more than 10 million yuan, to fully ensure the demand for first-line drugs.
Among them, 150000 boxes of abidol hydrochloride tablets (manosu) worth 4.05 million yuan were donated to the Red Cross Society of Wuzhong District, Suzhou City for the prevention and control of covid-19 pneumonia.
This time, the company plans to donate 400000 boxes of abidol hydrochloride tablets to places in need across the country, with a market value of more than 10 million yuan. At present, it has completed docking with the Red Cross Society and other relevant institutions in Wuzhong District of Suzhou and Jinhua City of Zhejiang. The company will coordinate logistics and drug distribution channels as planned, and send drugs to communities, isolation points and shelter hospitals as soon as possible, mainly to ensure the health of front-line medical personnel and patients.
It is reported that the drug is a broad-spectrum antiviral drug, which is mainly used to treat upper respiratory tract infections caused by influenza A and B viruses. Abidol mainly plays a unique antiviral role by preventing virus entry (inhibiting endocytosis and fusion), inducing the body to produce endogenous interferon, blocking virus replication, and improving the body's immunity (enhancing non-specific immunity and improving immune indexes).
The company said the medicines entered the influenza treatment program (2020 Edition) issued by the national health and Health Commission and the State Administration of traditional Chinese medicine, and won the 20192020 annual China family standing drug list. At the same time, it was included in the diagnosis and treatment plan of New Coronavirus pneumonia (Trial sixth, Seventh Edition and Eighth Edition), and many provinces have included the list of drug use for anti New Coronavirus pneumonia.